Black Diamond Therapeutics, Inc. — Cyborg Score 6/10
Solid
Clinical-stage oncology therapeutics
Strategic Profile
Black Diamond bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market. The company has outlicensed BDTX-4933 to increase focus on the development of silevertinib.
Cyborg Score Rationale
Black Diamond has strong Phase 2 data for silevertinib with clear differentiation in CNS penetration and resistance mechanisms. However, as a single-asset clinical-stage company, the pipeline is narrow and execution risk is concentrated. Extended cash runway and reduced burn provide some financial stability.
Top Insights
In May 2026, Black Diamond announced positive Phase 2 results for silevertinib in frontline NSCLC with EGFR non-classical mutations, reporting preliminary median progression-free survival of 15.2 months and robust CNS activity at 86%.
Q1 2026 results reflected lower costs and cash runway into 2028, continuing progress for lead candidate silevertinib. This extended runway reduces near-term financing pressure.
Net loss in Q1 2026 was $9.0 million versus net income of $56.5 million in Q1 2025, reflecting normalization of cash flow as licensing proceeds ended.
Named Competitors
Osimertinib — EGFR inhibitor for NSCLC
Erlotinib — First-generation EGFR TKI for EGFR-mutant NSCLC
Afatinib — Irreversible EGFR/HER2 inhibitor for EGFR-mutant NSCLC
Exkivity — Third-generation EGFR TKI for EGFR-mutant NSCLC
Recent Developments
(May 2026) Announced positive Phase 2 results for silevertinib in frontline NSCLC with EGFR non-classical mutations
(May 2026) Presented Phase 2 data at 2026 ASCO Annual Meeting (May 29–June 2, 2026)
(Q1 2026) Reported improved operational efficiencies and cash runway extended into 2028
Open the full interactive Black Diamond Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.